(Q42674269)

English

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

scientific article published on March 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Iversen P

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Tyrrell CJ

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Kaisary AV

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Anderson JB

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Baert L

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Tammela T

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Chamberlain M

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Carroll K

8

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Gotting-Smith K

9

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Blackledge GR

10

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

language of work or name

0 references

publication date

1 March 1998

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

389-396

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiandrogen monotherapy in the management of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Current clinical studies with a new nonsteroidal antiandrogen, Casodex

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in patients with advanced prostate cancer: a multinational perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Waning sexual function--the most important disease-specific distress for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sex or survival: trade-offs between quality and quantity of life

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient preferences: survival vs quality-of-life considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Worldwide activity and safety of bicalutamide: a summary review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900004-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(98)00004-1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42674269&oldid=1965201513"